http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 21 Jul 2025 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3391417-1%26h%3D733681236%26u%3Dhttps%253A%252F%252Fomegafunds.com%252F%26a%3DOmega%2BFunds&amp;esheet=54292877&amp;newsitemid=20250721567050&amp;lan=en-US&amp;anchor=Omega+Funds&amp;index=1&amp;md5=259a488ac6ee56960d46f3fd927c3f56" shape="rect"><b>Omega Funds</b></a>, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. </p><p> Since its inception in http://www.streetinsider.com/Press+Releases/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html Mon, 21 Jul 2025 07:00:00 -0400 A.50114195 BBNX BCAX IMGO KMTS MORF O.57196001 UPB http://www.streetinsider.com/Press+Releases/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3391417-1%26h%3D733681236%26u%3Dhttps%253A%252F%252Fomegafunds.com%252F%26a%3DOmega%2BFunds&amp;esheet=54292877&amp;newsitemid=20250721567050&amp;lan=en-US&amp;anchor=Omega+Funds&amp;index=1&amp;md5=259a488ac6ee56960d46f3fd927c3f56" shape="rect"><b>Omega Funds</b></a>, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. </p><p> Since its inception in http://www.streetinsider.com/Press+Releases/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html Mon, 21 Jul 2025 07:00:00 -0400 A.50114195 BBNX BCAX IMGO KMTS MORF O.57196001 UPB http://www.streetinsider.com/Press+Releases/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3391417-1%26h%3D733681236%26u%3Dhttps%253A%252F%252Fomegafunds.com%252F%26a%3DOmega%2BFunds&amp;esheet=54292877&amp;newsitemid=20250721567050&amp;lan=en-US&amp;anchor=Omega+Funds&amp;index=1&amp;md5=259a488ac6ee56960d46f3fd927c3f56" shape="rect"><b>Omega Funds</b></a>, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. </p><p> Since its inception in http://www.streetinsider.com/Press+Releases/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html Mon, 21 Jul 2025 07:00:00 -0400 A.50114195 BBNX BCAX IMGO KMTS MORF O.57196001 UPB http://www.streetinsider.com/Press+Releases/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3391417-1%26h%3D733681236%26u%3Dhttps%253A%252F%252Fomegafunds.com%252F%26a%3DOmega%2BFunds&amp;esheet=54292877&amp;newsitemid=20250721567050&amp;lan=en-US&amp;anchor=Omega+Funds&amp;index=1&amp;md5=259a488ac6ee56960d46f3fd927c3f56" shape="rect"><b>Omega Funds</b></a>, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. </p><p> Since its inception in http://www.streetinsider.com/Press+Releases/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html Mon, 21 Jul 2025 07:00:00 -0400 A.50114195 BBNX BCAX IMGO KMTS MORF O.57196001 UPB http://www.streetinsider.com/Press+Releases/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3391417-1%26h%3D733681236%26u%3Dhttps%253A%252F%252Fomegafunds.com%252F%26a%3DOmega%2BFunds&amp;esheet=54292877&amp;newsitemid=20250721567050&amp;lan=en-US&amp;anchor=Omega+Funds&amp;index=1&amp;md5=259a488ac6ee56960d46f3fd927c3f56" shape="rect"><b>Omega Funds</b></a>, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. </p><p> Since its inception in http://www.streetinsider.com/Press+Releases/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html Mon, 21 Jul 2025 07:00:00 -0400 A.50114195 BBNX BCAX IMGO KMTS MORF O.57196001 UPB http://www.streetinsider.com/Press+Releases/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3391417-1%26h%3D733681236%26u%3Dhttps%253A%252F%252Fomegafunds.com%252F%26a%3DOmega%2BFunds&amp;esheet=54292877&amp;newsitemid=20250721567050&amp;lan=en-US&amp;anchor=Omega+Funds&amp;index=1&amp;md5=259a488ac6ee56960d46f3fd927c3f56" shape="rect"><b>Omega Funds</b></a>, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. </p><p> Since its inception in http://www.streetinsider.com/Press+Releases/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html Mon, 21 Jul 2025 07:00:00 -0400 A.50114195 BBNX BCAX IMGO KMTS MORF O.57196001 UPB http://www.streetinsider.com/Press+Releases/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3391417-1%26h%3D733681236%26u%3Dhttps%253A%252F%252Fomegafunds.com%252F%26a%3DOmega%2BFunds&amp;esheet=54292877&amp;newsitemid=20250721567050&amp;lan=en-US&amp;anchor=Omega+Funds&amp;index=1&amp;md5=259a488ac6ee56960d46f3fd927c3f56" shape="rect"><b>Omega Funds</b></a>, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. </p><p> Since its inception in http://www.streetinsider.com/Press+Releases/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html Mon, 21 Jul 2025 07:00:00 -0400 A.50114195 BBNX BCAX IMGO KMTS MORF O.57196001 UPB http://www.streetinsider.com/Press+Releases/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3391417-1%26h%3D733681236%26u%3Dhttps%253A%252F%252Fomegafunds.com%252F%26a%3DOmega%2BFunds&amp;esheet=54292877&amp;newsitemid=20250721567050&amp;lan=en-US&amp;anchor=Omega+Funds&amp;index=1&amp;md5=259a488ac6ee56960d46f3fd927c3f56" shape="rect"><b>Omega Funds</b></a>, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. </p><p> Since its inception in http://www.streetinsider.com/Press+Releases/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html Mon, 21 Jul 2025 07:00:00 -0400 A.50114195 BBNX BCAX IMGO KMTS MORF O.57196001 UPB http://www.streetinsider.com/Business+Wire/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3391417-1%26h%3D733681236%26u%3Dhttps%253A%252F%252Fomegafunds.com%252F%26a%3DOmega%2BFunds&amp;esheet=54292877&amp;newsitemid=20250721567050&amp;lan=en-US&amp;anchor=Omega+Funds&amp;index=1&amp;md5=259a488ac6ee56960d46f3fd927c3f56" shape="rect"><b>Omega Funds</b></a>, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. </p><p> Since its inception in http://www.streetinsider.com/Business+Wire/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html Mon, 21 Jul 2025 07:00:00 -0400 A.50114195 BBNX BCAX IMGO KMTS MORF O.57196001 UPB http://www.streetinsider.com/Business+Wire/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3391417-1%26h%3D733681236%26u%3Dhttps%253A%252F%252Fomegafunds.com%252F%26a%3DOmega%2BFunds&amp;esheet=54292877&amp;newsitemid=20250721567050&amp;lan=en-US&amp;anchor=Omega+Funds&amp;index=1&amp;md5=259a488ac6ee56960d46f3fd927c3f56" shape="rect"><b>Omega Funds</b></a>, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. </p><p> Since its inception in http://www.streetinsider.com/Business+Wire/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html Mon, 21 Jul 2025 07:00:00 -0400 A.50114195 BBNX BCAX IMGO KMTS MORF O.57196001 UPB http://www.streetinsider.com/Business+Wire/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3391417-1%26h%3D733681236%26u%3Dhttps%253A%252F%252Fomegafunds.com%252F%26a%3DOmega%2BFunds&amp;esheet=54292877&amp;newsitemid=20250721567050&amp;lan=en-US&amp;anchor=Omega+Funds&amp;index=1&amp;md5=259a488ac6ee56960d46f3fd927c3f56" shape="rect"><b>Omega Funds</b></a>, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. </p><p> Since its inception in http://www.streetinsider.com/Business+Wire/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html Mon, 21 Jul 2025 07:00:00 -0400 A.50114195 BBNX BCAX IMGO KMTS MORF O.57196001 UPB http://www.streetinsider.com/Business+Wire/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3391417-1%26h%3D733681236%26u%3Dhttps%253A%252F%252Fomegafunds.com%252F%26a%3DOmega%2BFunds&amp;esheet=54292877&amp;newsitemid=20250721567050&amp;lan=en-US&amp;anchor=Omega+Funds&amp;index=1&amp;md5=259a488ac6ee56960d46f3fd927c3f56" shape="rect"><b>Omega Funds</b></a>, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. </p><p> Since its inception in http://www.streetinsider.com/Business+Wire/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html Mon, 21 Jul 2025 07:00:00 -0400 A.50114195 BBNX BCAX IMGO KMTS MORF O.57196001 UPB http://www.streetinsider.com/Business+Wire/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3391417-1%26h%3D733681236%26u%3Dhttps%253A%252F%252Fomegafunds.com%252F%26a%3DOmega%2BFunds&amp;esheet=54292877&amp;newsitemid=20250721567050&amp;lan=en-US&amp;anchor=Omega+Funds&amp;index=1&amp;md5=259a488ac6ee56960d46f3fd927c3f56" shape="rect"><b>Omega Funds</b></a>, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. </p><p> Since its inception in http://www.streetinsider.com/Business+Wire/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html Mon, 21 Jul 2025 07:00:00 -0400 A.50114195 BBNX BCAX IMGO KMTS MORF O.57196001 UPB http://www.streetinsider.com/Business+Wire/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3391417-1%26h%3D733681236%26u%3Dhttps%253A%252F%252Fomegafunds.com%252F%26a%3DOmega%2BFunds&amp;esheet=54292877&amp;newsitemid=20250721567050&amp;lan=en-US&amp;anchor=Omega+Funds&amp;index=1&amp;md5=259a488ac6ee56960d46f3fd927c3f56" shape="rect"><b>Omega Funds</b></a>, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. </p><p> Since its inception in http://www.streetinsider.com/Business+Wire/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html Mon, 21 Jul 2025 07:00:00 -0400 A.50114195 BBNX BCAX IMGO KMTS MORF O.57196001 UPB http://www.streetinsider.com/Business+Wire/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3391417-1%26h%3D733681236%26u%3Dhttps%253A%252F%252Fomegafunds.com%252F%26a%3DOmega%2BFunds&amp;esheet=54292877&amp;newsitemid=20250721567050&amp;lan=en-US&amp;anchor=Omega+Funds&amp;index=1&amp;md5=259a488ac6ee56960d46f3fd927c3f56" shape="rect"><b>Omega Funds</b></a>, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. </p><p> Since its inception in http://www.streetinsider.com/Business+Wire/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html Mon, 21 Jul 2025 07:00:00 -0400 A.50114195 BBNX BCAX IMGO KMTS MORF O.57196001 UPB http://www.streetinsider.com/Business+Wire/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3391417-1%26h%3D733681236%26u%3Dhttps%253A%252F%252Fomegafunds.com%252F%26a%3DOmega%2BFunds&amp;esheet=54292877&amp;newsitemid=20250721567050&amp;lan=en-US&amp;anchor=Omega+Funds&amp;index=1&amp;md5=259a488ac6ee56960d46f3fd927c3f56" shape="rect"><b>Omega Funds</b></a>, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. </p><p> Since its inception in http://www.streetinsider.com/Business+Wire/Omega+Funds+Closes+Oversubscribed+%24647+Million+Fund+VIII+to+Invest+in+Transformative+Life+Science+Companies/25072799.html Mon, 21 Jul 2025 07:00:00 -0400 A.50114195 BBNX BCAX IMGO KMTS MORF O.57196001 UPB